1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legal & IP

Class-Action Suit Alleges Medtronic’s Rosy Forecast For MiniMed780G Misled Investors

 
• By Elizabeth Orr

The lawsuit says that Medtronic continued to predict that the new insulin pump would be FDA-approved shortly, even as other regulatory issues and recalls in the diabetes division made that less likely.

Photo illustration of a black-and-white landscape with a portion tinted pink through rose-colored glasses.
• Source: Shutterstock

Medtronic plc misled shareholders about the future of the MiniMed 780G insulin pump, a class-action lawsuit recently filed in Minnesota federal court argues.

The suit, which was filed on 8 September, alleges that the medtech giant falsely told investors that the system was “on track” for imminent approval by the US Food and Drug Administration, even as regulatory

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Policy & Regulation